Illumina, Inc. (ILMN)

405,14 +5,63 (+1,41%) Al cierre: 04:00PM EST

Illumina, Inc.

5200 Illumina Way
San Diego, CA 92122
United States
858 202 4500
https://www.illumina.com

Sector(es): Healthcare
Sector: Diagnostics & Research
Empleados a tiempo completo: 7800

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Francis A. deSouza	CEO & Director	N/A	N/A	1971
Mr. Sam A. Samad	Chief Financial Officer	716,04k	N/A	1970
Dr. Alexander Aravanis M.D., Ph.D.	CTO & Head of Research and Product Devel.	416,48k	N/A	1976
Ms. Susan H. Tousi	Chief Commercial Officer	655,31k	N/A	1969
Stephanie Campos	Pres	N/A	N/A	N/A
Mr. Kevin Carl Pegels	Chief of Global Operations	N/A	N/A	N/A
Mr. Jose A. Torres Jr.	Chief Accounting Officer & VP	N/A	N/A	1975
Mr. Steve Phillpott	Sr. VP & Chief Information Officer	N/A	N/A	N/A
Ms. Sallilyn Schwartz	VP of Investor Relations	N/A	N/A	N/A
Mr. Charles E. Dadswell	Sr. VP, Gen. Counsel & Sec.	N/A	N/A	1959

Los importes son a partir de 31 de diciembre de 2020 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has collaboration agreements with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer; LetsGetChecked to track COVID-19 variants in California; and Merck & Co., Inc. to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency. The company was incorporated in 1998 and is headquartered in San Diego, California.

Gobierno corporativo

El ISS Governance QualityScore de Illumina, Inc., a día 26 de septiembre de 2021, es 6. Las puntuaciones base son Auditoría: 3; Tablero: 1; Derechos de los accionistas: 6; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.